These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28734794)

  • 1. Botulinum toxin A is effective to treat tension-type headache caused by hemifacial spasm.
    Mizuma A; Nagata E; Yasuda T; Kouchi M; Nakayama T; Honma K; Tokuoka K; Kitagawa Y; Nogawa S; Takizawa S
    J Clin Neurosci; 2017 Oct; 44():284-288. PubMed ID: 28734794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Facial asymmetry in patients with hemifacial spasm before and after botulinum toxin A treatment.
    Xiao L; Pan Y; Zhang X; Hu Y; Cai L; Nie Z; Pan L; Li B; He Y; Jin L
    Neurol Sci; 2016 Nov; 37(11):1807-1813. PubMed ID: 27431279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Headache in hemifacial spasm patients.
    Peeraully T; Tan SF; Fook-Chong SM; Prakash KM; Tan EK
    Acta Neurol Scand; 2013 May; 127(5):e24-7. PubMed ID: 23311349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does needle size matter? Effects of micro-hypodermic needle injections of botulinum toxin type A in patients with hemifacial spasm.
    Maytharakcheep S; Phokaewvarangkul O; Bhidayasiri R
    Parkinsonism Relat Disord; 2024 Jan; 118():105950. PubMed ID: 38081119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies.
    Tambasco N; Filidei M; Nigro P; Parnetti L; Simoni S
    Toxins (Basel); 2021 Dec; 13(12):. PubMed ID: 34941718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synkinesis in primary and postparalytic hemifacial spasm: Clinical features and therapeutic outcomes of botulinum toxin A treatment.
    Su JH; Yang MN; Teng F; Zhang XL; Pan YG; Hu Y; Xiao LB; Pan LZ; Li LX; Jin LJ
    Toxicon; 2020 Sep; 184():122-126. PubMed ID: 32553733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life in hemifacial spasm patient after treatment with botulinum toxin A; a 24-week, double-blind, randomized, cross-over comparison of Dysport and Neuronox study.
    Kongsengdao S; Kritalukkul S
    J Med Assoc Thai; 2012 Mar; 95 Suppl 3():S48-54. PubMed ID: 22619887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features and response to botulinum toxin in primary and secondary hemifacial spasm.
    Pandey S; Jain S
    Neurol India; 2018; 66(4):1036-1042. PubMed ID: 30038089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin type B (Myobloc) in subjects with hemifacial spasm: results from an open-label, dose-escalation safety study.
    Trosch RM; Adler CH; Pappert EJ
    Mov Disord; 2007 Jul; 22(9):1258-64. PubMed ID: 17588242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.
    Lolekha P; Choolam A; Kulkantrakorn K
    Neurol Sci; 2017 Nov; 38(11):2031-2036. PubMed ID: 28884242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemifacial spasm non-motor and motor-related symptoms and their response to botulinum toxin therapy.
    Rudzińska M; Wójcik M; Szczudlik A
    J Neural Transm (Vienna); 2010 Jun; 117(6):765-72. PubMed ID: 20467763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blinking Parameters Do Not Normalize After Botulinum Toxin Therapy in Blepharospasm and Hemifacial Spasm Patients.
    Gameiro GR; Osaki MH; Yabumoto C; Osaki T; Garcia DM; Belfort R; Cruz AAV; Osaki TH
    J Neuroophthalmol; 2023 Dec; 43(4):563-568. PubMed ID: 37307066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin in the treatment of rare head and neck pain syndromes: a systematic review of the literature.
    Sycha T; Kranz G; Auff E; Schnider P
    J Neurol; 2004 Feb; 251 Suppl 1():I19-30. PubMed ID: 14991339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the Hemifacial Spasm Grading Scale: a clinical tool for hemifacial spasm.
    Tambasco N; Simoni S; Sacchini E; Eusebi P; Marsili E; Nigro P; Brahimi E; Paoletti FP; Romoli M; Calabresi P
    Neurol Sci; 2019 Sep; 40(9):1887-1892. PubMed ID: 31076941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of botulinum toxin on auditory disturbances in hemifacial spasm.
    Rudzińska M; Wójcik M; Zajdel K; Hydzik-Sobocińska K; Malec M; Hartel M; Składzień J; Szczudlik A
    Neurol Neurochir Pol; 2012; 46(1):29-36. PubMed ID: 22426760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subjective versus objective symptom intensities ratings in cervical dystonia and hemifacial spasm across a botulinum neurotoxin cycle.
    Wöllner J; Weise D; Leplow B
    Brain Behav; 2021 Mar; 11(3):e02023. PubMed ID: 33403834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subjective and Objective Measures in the Treatment of Hemifacial Spasm With OnabotulinumtoxinA.
    Chundury RV; D'Angelo AS; Couch SM; Holds JB
    Ophthalmic Plast Reconstr Surg; 2016; 32(2):133-7. PubMed ID: 25811161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive effect of self-exercise following Botulinum toxin injection on the permanence of the recovery among the patients with HFS and BFS: A clinical trial.
    Sari ÜS; Eroglu M; Büyükşerbetçi G; Tokucoglu F; Sahin N
    Medicine (Baltimore); 2024 Jun; 103(24):e38215. PubMed ID: 38875371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of a new hemifacial spasm grading questionnaire (HFS score) assessing clinical and quality of life parameters.
    Wabbels B; Yaqubi A
    J Neural Transm (Vienna); 2021 Jun; 128(6):793-802. PubMed ID: 33963897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term adherence and response to botulinum toxin in different indications.
    Lee JI; Jansen A; Samadzadeh S; Kahlen U; Moll M; Ringelstein M; Soncin G; Bigalke H; Aktas O; Moldovan AS; Waskoenig J; Jander S; Gliem M; Schnitzler A; Hartung HP; Hefter H; Albrecht P
    Ann Clin Transl Neurol; 2021 Jan; 8(1):15-28. PubMed ID: 33259153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.